Wenxin Xu
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Cancer Diagnosis and Treatment, Systemic Sclerosis and Related Diseases, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Progressive immune dysfunction with advancing disease stage in renal cell carcinoma(2021)492 cited
- → Checkpoint inhibitor immunotherapy in kidney cancer(2020)267 cited
- → Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models(2015)222 cited
- → Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma(2013)193 cited
- → Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19(2021)184 cited
- → Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study(2015)160 cited
- → IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas(2016)156 cited
- → Novel Human Interleukin-15 Agonists(2009)152 cited
- → Compensatory Mutations Restore Fitness during the Evolution of Dihydrofolate Reductase(2010)114 cited
- → Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors(2022)110 cited